These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 17598785)

  • 1. Preliminary estimates of cost-effectiveness for marital therapy.
    Caldwell BE; Woolley SR; Caldwell CJ
    J Marital Fam Ther; 2007 Jul; 33(3):392-405. PubMed ID: 17598785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing the costs, benefits, cost-benefit ratio, and cost-effectiveness of marital and family treatments: why we should and how we can.
    Fals-Stewart W; Yates BT; Klostermann K
    J Fam Psychol; 2005 Mar; 19(1):28-39. PubMed ID: 15796650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benefit adequacy among elderly Social Security retired-worker beneficiaries and the SSI federal benefit rate.
    Rupp K; Strand A; Davies P; Sears J
    Soc Secur Bull; 2007; 67(3):29-51. PubMed ID: 18605217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-benefit and cost-effectiveness analyses of behavioral marital therapy as an addition to outpatient alcoholism treatment.
    O'Farrell TJ; Choquette KA; Cutter HS; Floyd FJ; Bayog R; Brown ED; Lowe J; Chan A; Deneault P
    J Subst Abuse; 1996; 8(2):145-66. PubMed ID: 8880657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Case for Insurance Reimbursement of Couple Therapy.
    Clawson RE; Davis SY; Miller RB; Webster TN
    J Marital Fam Ther; 2018 Jul; 44(3):512-526. PubMed ID: 28833253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are psychological treatments for depression in primary care cost-effective?
    Bosmans JE; van Schaik DJ; de Bruijne MC; van Hout HP; van Marwijk HW; van Tulder MW; Stalman WA
    J Ment Health Policy Econ; 2008 Mar; 11(1):3-15. PubMed ID: 18424872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of group psychotherapy for depression in Uganda.
    Siskind D; Baingana F; Kim J
    J Ment Health Policy Econ; 2008 Sep; 11(3):127-33. PubMed ID: 18806302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ryan White CARE Act Title IV programs: a preliminary characterization of benefits and costs.
    Abramowitz S; Greene D
    AIDS Public Policy J; 2005; 20(3-4):108-25. PubMed ID: 17624034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medicaid managed care and the distribution of societal costs for persons with severe mental illness.
    Shern DL; Jones K; Chen HJ; Jordan N; Ramoni-Perazzi J; Boothroyd RA
    Am J Psychiatry; 2008 Feb; 165(2):254-60. PubMed ID: 18198269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How does the persistence of depression influence the continuity and type of health insurance and coverage limits on mental health therapy?
    Masaquel A; Wells K; Ettner SL
    J Ment Health Policy Econ; 2007 Sep; 10(3):133-44. PubMed ID: 17890830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient preferences for depression treatment programs and willingness to pay for treatment.
    Morey E; Thacher JA; Craighead WE
    J Ment Health Policy Econ; 2007 Jun; 10(2):73-85. PubMed ID: 17603148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does public insurance provide better financial protection against rising health care costs for families of children with special health care needs?
    Yu H; Dick AW; Szilagyi PG
    Med Care; 2008 Oct; 46(10):1064-70. PubMed ID: 18815528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening, prevention and treatment of cervical cancer -- a global and regional generalized cost-effectiveness analysis.
    Ginsberg GM; Edejer TT; Lauer JA; Sepulveda C
    Vaccine; 2009 Oct; 27(43):6060-79. PubMed ID: 19647813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. American Society of Clinical Oncology guidance statement: the cost of cancer care.
    Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
    J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of a mixed-gender aftercare program for substance abuse: decomposing measured and unmeasured gender differences.
    Yeom HS; Shepard DS
    J Ment Health Policy Econ; 2007 Dec; 10(4):207-19. PubMed ID: 18166831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of integrated care for people with HIV, chronic mental illness and substance abuse disorders.
    Weaver MR; Conover CJ; Proescholdbell RJ; Arno PS; Ang A; Uldall KK; Ettner SL
    J Ment Health Policy Econ; 2009 Mar; 12(1):33-46. PubMed ID: 19346565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disability benefit coverage and program interactions in the working-age population.
    Rupp K; Davies PS; Strand A
    Soc Secur Bull; 2008; 68(1):1-30. PubMed ID: 18837269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A couples intervention for patients facing advanced cancer and their spouse caregivers: outcomes of a pilot study.
    McLean LM; Jones JM; Rydall AC; Walsh A; Esplen MJ; Zimmermann C; Rodin GM
    Psychooncology; 2008 Nov; 17(11):1152-6. PubMed ID: 18213694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Injury and illness costs in the Certified Safe Farm study.
    Donham KJ; Rautiainen RH; Lange JL; Schneiders S
    J Rural Health; 2007; 23(4):348-55. PubMed ID: 17868242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.